Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 19 | 2024 | 8986 | 0.910 |
Why?
|
Magnetic Resonance Imaging | 29 | 2024 | 36290 | 0.910 |
Why?
|
Glioblastoma | 11 | 2019 | 3484 | 0.860 |
Why?
|
Posterior Leukoencephalopathy Syndrome | 1 | 2023 | 50 | 0.840 |
Why?
|
Guillain-Barre Syndrome | 1 | 2023 | 125 | 0.780 |
Why?
|
Spectrum Analysis, Raman | 3 | 2014 | 237 | 0.550 |
Why?
|
Epilepsy | 2 | 2022 | 3267 | 0.530 |
Why?
|
Image Interpretation, Computer-Assisted | 7 | 2024 | 3340 | 0.530 |
Why?
|
Diffusion Magnetic Resonance Imaging | 5 | 2018 | 2782 | 0.470 |
Why?
|
Astrocytoma | 2 | 2015 | 775 | 0.430 |
Why?
|
Histocytological Preparation Techniques | 1 | 2012 | 33 | 0.420 |
Why?
|
Tomography, X-Ray Computed | 5 | 2017 | 20509 | 0.390 |
Why?
|
Glioma | 6 | 2024 | 3420 | 0.380 |
Why?
|
Perfusion Imaging | 1 | 2013 | 196 | 0.380 |
Why?
|
Cell Tracking | 1 | 2012 | 138 | 0.380 |
Why?
|
Multiple System Atrophy | 2 | 2022 | 129 | 0.370 |
Why?
|
Head | 1 | 2017 | 922 | 0.370 |
Why?
|
Cranial Fossa, Posterior | 1 | 2011 | 135 | 0.360 |
Why?
|
Creutzfeldt-Jakob Syndrome | 3 | 2006 | 91 | 0.350 |
Why?
|
Adenoma | 2 | 2011 | 2148 | 0.340 |
Why?
|
Ciliary Body | 1 | 2009 | 166 | 0.330 |
Why?
|
Echo-Planar Imaging | 2 | 2014 | 657 | 0.320 |
Why?
|
Radiation Dosage | 1 | 2017 | 1958 | 0.310 |
Why?
|
Neuronavigation | 1 | 2009 | 164 | 0.300 |
Why?
|
Mesencephalon | 1 | 2009 | 332 | 0.290 |
Why?
|
Contrast Media | 2 | 2017 | 5305 | 0.290 |
Why?
|
Nervous System Diseases | 1 | 2017 | 1647 | 0.280 |
Why?
|
Uveal Neoplasms | 1 | 2009 | 341 | 0.270 |
Why?
|
Cerebrovascular Disorders | 1 | 2013 | 1501 | 0.260 |
Why?
|
Blood Flow Velocity | 1 | 2009 | 1377 | 0.240 |
Why?
|
Image Enhancement | 5 | 2012 | 2881 | 0.230 |
Why?
|
Brain | 14 | 2022 | 26951 | 0.230 |
Why?
|
Dacarbazine | 3 | 2015 | 560 | 0.230 |
Why?
|
Critical Care | 1 | 2017 | 2699 | 0.230 |
Why?
|
Pregnancy Complications | 1 | 2017 | 2942 | 0.220 |
Why?
|
Skin | 2 | 2017 | 4466 | 0.220 |
Why?
|
Pituitary Neoplasms | 1 | 2011 | 1313 | 0.200 |
Why?
|
Supranuclear Palsy, Progressive | 1 | 2022 | 80 | 0.200 |
Why?
|
Antibodies, Monoclonal | 2 | 2017 | 9185 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2019 | 9276 | 0.190 |
Why?
|
Deep Brain Stimulation | 1 | 2009 | 820 | 0.190 |
Why?
|
Immunotherapy | 1 | 2017 | 4642 | 0.180 |
Why?
|
Pattern Recognition, Automated | 3 | 2012 | 994 | 0.180 |
Why?
|
Tomography, Optical Coherence | 1 | 2012 | 2884 | 0.160 |
Why?
|
Cerebrovascular Circulation | 1 | 2009 | 2733 | 0.160 |
Why?
|
Parkinson Disease | 2 | 2022 | 2859 | 0.150 |
Why?
|
Angiography, Digital Subtraction | 1 | 2019 | 334 | 0.150 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2019 | 126 | 0.150 |
Why?
|
Algorithms | 8 | 2012 | 13981 | 0.150 |
Why?
|
Antineoplastic Agents | 3 | 2019 | 13630 | 0.150 |
Why?
|
Sarcoma | 1 | 2008 | 1786 | 0.150 |
Why?
|
Sensitivity and Specificity | 8 | 2020 | 14660 | 0.140 |
Why?
|
Humans | 48 | 2024 | 760621 | 0.140 |
Why?
|
Uncertainty | 1 | 2021 | 754 | 0.140 |
Why?
|
Morpholines | 1 | 2019 | 583 | 0.130 |
Why?
|
Tomography, Spiral Computed | 1 | 2017 | 273 | 0.120 |
Why?
|
Disease-Free Survival | 4 | 2015 | 6828 | 0.120 |
Why?
|
Aminopyridines | 1 | 2019 | 564 | 0.120 |
Why?
|
Brain Mapping | 4 | 2019 | 6568 | 0.110 |
Why?
|
Middle Aged | 21 | 2024 | 220352 | 0.110 |
Why?
|
Female | 27 | 2024 | 391270 | 0.110 |
Why?
|
Survival Rate | 3 | 2017 | 12808 | 0.100 |
Why?
|
Male | 22 | 2024 | 359744 | 0.100 |
Why?
|
Adult | 21 | 2024 | 219994 | 0.100 |
Why?
|
Area Under Curve | 1 | 2015 | 1636 | 0.100 |
Why?
|
Reproducibility of Results | 7 | 2013 | 20080 | 0.100 |
Why?
|
Preoperative Care | 2 | 2011 | 2256 | 0.090 |
Why?
|
Retrospective Studies | 11 | 2022 | 80372 | 0.090 |
Why?
|
Diagnosis, Differential | 7 | 2022 | 12965 | 0.090 |
Why?
|
Public Health | 1 | 2024 | 2653 | 0.090 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2022 | 1846 | 0.090 |
Why?
|
Brain Chemistry | 1 | 2014 | 959 | 0.090 |
Why?
|
Cranial Nerve Neoplasms | 1 | 2011 | 134 | 0.090 |
Why?
|
Stroke | 2 | 2012 | 9962 | 0.090 |
Why?
|
Demyelinating Diseases | 1 | 2012 | 351 | 0.090 |
Why?
|
Treatment Outcome | 7 | 2017 | 65017 | 0.090 |
Why?
|
Ventral Thalamic Nuclei | 1 | 2009 | 43 | 0.080 |
Why?
|
Patient Selection | 1 | 2022 | 4283 | 0.080 |
Why?
|
Language | 1 | 2019 | 1533 | 0.080 |
Why?
|
Subtraction Technique | 1 | 2012 | 510 | 0.080 |
Why?
|
Medicine, Traditional | 1 | 2009 | 87 | 0.080 |
Why?
|
Image Processing, Computer-Assisted | 4 | 2015 | 8950 | 0.080 |
Why?
|
Tuberculosis, Cutaneous | 1 | 2008 | 17 | 0.080 |
Why?
|
Tuberculosis, Central Nervous System | 1 | 2008 | 16 | 0.080 |
Why?
|
Vagus Nerve | 1 | 2011 | 458 | 0.080 |
Why?
|
Microelectrodes | 1 | 2009 | 304 | 0.080 |
Why?
|
Microscopy | 1 | 2013 | 885 | 0.080 |
Why?
|
Staining and Labeling | 1 | 2012 | 1089 | 0.080 |
Why?
|
Neurosurgical Procedures | 2 | 2019 | 2056 | 0.070 |
Why?
|
ROC Curve | 1 | 2015 | 3568 | 0.070 |
Why?
|
Substantia Nigra | 1 | 2009 | 350 | 0.070 |
Why?
|
Neoadjuvant Therapy | 1 | 2019 | 2821 | 0.070 |
Why?
|
Luminescent Measurements | 1 | 2009 | 378 | 0.070 |
Why?
|
Heme Oxygenase-1 | 1 | 2009 | 364 | 0.070 |
Why?
|
Imaging, Three-Dimensional | 3 | 2014 | 4048 | 0.070 |
Why?
|
Subthalamic Nucleus | 1 | 2009 | 193 | 0.070 |
Why?
|
Prognosis | 3 | 2018 | 29658 | 0.070 |
Why?
|
Brain Diseases | 2 | 2008 | 1540 | 0.070 |
Why?
|
Amnesia, Anterograde | 1 | 2006 | 20 | 0.070 |
Why?
|
Hemoglobins | 1 | 2012 | 1521 | 0.070 |
Why?
|
Neurilemmoma | 1 | 2011 | 523 | 0.070 |
Why?
|
Survival Analysis | 2 | 2015 | 10182 | 0.070 |
Why?
|
Mice, Nude | 1 | 2012 | 3607 | 0.070 |
Why?
|
Encephalitis, Viral | 1 | 2006 | 59 | 0.070 |
Why?
|
Sex Distribution | 1 | 2011 | 2295 | 0.060 |
Why?
|
Herpesvirus 6, Human | 1 | 2006 | 97 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2011 | 1791 | 0.060 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2007 | 3765 | 0.060 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2008 | 662 | 0.060 |
Why?
|
Angiogenesis Inhibitors | 2 | 2012 | 2049 | 0.060 |
Why?
|
Inflammation | 1 | 2023 | 10756 | 0.050 |
Why?
|
Radiation Injuries | 1 | 2011 | 1183 | 0.050 |
Why?
|
Intensive Care Units | 1 | 2017 | 3736 | 0.050 |
Why?
|
Quinazolines | 1 | 2010 | 1363 | 0.050 |
Why?
|
Carcinoma, Basal Cell | 1 | 2008 | 559 | 0.050 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2007 | 618 | 0.050 |
Why?
|
Monitoring, Intraoperative | 1 | 2009 | 942 | 0.050 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2007 | 547 | 0.050 |
Why?
|
Neoplasm, Residual | 2 | 2020 | 1007 | 0.050 |
Why?
|
Neoplasm Invasiveness | 1 | 2011 | 3618 | 0.050 |
Why?
|
Disease Models, Animal | 2 | 2012 | 18137 | 0.050 |
Why?
|
Cerebellar Neoplasms | 1 | 2007 | 587 | 0.050 |
Why?
|
Epidermal Cyst | 1 | 2002 | 64 | 0.050 |
Why?
|
Brain Abscess | 1 | 2002 | 120 | 0.050 |
Why?
|
Disease Progression | 2 | 2019 | 13502 | 0.050 |
Why?
|
Scoliosis | 1 | 2008 | 735 | 0.050 |
Why?
|
Piperidines | 1 | 2010 | 1650 | 0.050 |
Why?
|
Lipids | 1 | 2012 | 3336 | 0.050 |
Why?
|
Aged | 11 | 2020 | 169152 | 0.050 |
Why?
|
Artifacts | 1 | 2009 | 1898 | 0.050 |
Why?
|
Decision Trees | 1 | 2022 | 506 | 0.050 |
Why?
|
Receptors, GABA | 1 | 2022 | 305 | 0.050 |
Why?
|
Models, Neurological | 1 | 2008 | 1758 | 0.040 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2008 | 930 | 0.040 |
Why?
|
Intraoperative Period | 1 | 2020 | 516 | 0.040 |
Why?
|
Neuroglia | 1 | 2005 | 944 | 0.040 |
Why?
|
Neoplasms, Second Primary | 1 | 2007 | 1056 | 0.040 |
Why?
|
Esophageal Neoplasms | 1 | 2008 | 1648 | 0.040 |
Why?
|
Software | 1 | 2012 | 4419 | 0.040 |
Why?
|
Stereotaxic Techniques | 1 | 2020 | 549 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 15289 | 0.040 |
Why?
|
Proteins | 1 | 2012 | 6029 | 0.040 |
Why?
|
Animals | 6 | 2022 | 167963 | 0.040 |
Why?
|
Prospective Studies | 2 | 2022 | 54303 | 0.030 |
Why?
|
alpha-Synuclein | 1 | 2022 | 749 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2010 | 12531 | 0.030 |
Why?
|
Pregnancy | 1 | 2017 | 29749 | 0.030 |
Why?
|
Cell Line, Tumor | 1 | 2012 | 16939 | 0.030 |
Why?
|
Postoperative Period | 1 | 2020 | 1818 | 0.030 |
Why?
|
Cohort Studies | 1 | 2018 | 41335 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2010 | 14495 | 0.030 |
Why?
|
Time Factors | 2 | 2019 | 40165 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2012 | 22023 | 0.030 |
Why?
|
Hematoxylin | 1 | 2013 | 60 | 0.030 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2013 | 69 | 0.030 |
Why?
|
Mice | 4 | 2013 | 81208 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2019 | 3602 | 0.030 |
Why?
|
Neoplasm Staging | 1 | 2007 | 11152 | 0.030 |
Why?
|
Color | 1 | 2013 | 298 | 0.030 |
Why?
|
Software Validation | 1 | 2012 | 59 | 0.030 |
Why?
|
Functional Laterality | 1 | 2019 | 2253 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2010 | 11712 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2008 | 6315 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 22072 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2019 | 58995 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3529 | 0.020 |
Why?
|
Melanoma | 1 | 2008 | 5697 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2013 | 2014 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2008 | 5799 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2008 | 6853 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2011 | 15697 | 0.020 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2008 | 61 | 0.020 |
Why?
|
Luciferases | 1 | 2009 | 716 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2006 | 5649 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2010 | 877 | 0.020 |
Why?
|
Diverticulitis | 1 | 2010 | 182 | 0.020 |
Why?
|
Observer Variation | 1 | 2013 | 2601 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2007 | 369 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 544 | 0.020 |
Why?
|
Mathematical Computing | 1 | 2006 | 143 | 0.020 |
Why?
|
Urban Health | 1 | 2008 | 533 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2008 | 11345 | 0.020 |
Why?
|
Markov Chains | 1 | 2009 | 968 | 0.020 |
Why?
|
Peru | 1 | 2008 | 869 | 0.020 |
Why?
|
Neurons | 1 | 2005 | 9426 | 0.020 |
Why?
|
Young Adult | 3 | 2019 | 58741 | 0.010 |
Why?
|
Neutropenia | 1 | 2010 | 884 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2008 | 13262 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2015 | 5201 | 0.010 |
Why?
|
Diffusion | 1 | 2006 | 813 | 0.010 |
Why?
|
Risk Factors | 1 | 2011 | 74359 | 0.010 |
Why?
|
Drug Synergism | 1 | 2008 | 1754 | 0.010 |
Why?
|
Pulvinar | 1 | 2003 | 21 | 0.010 |
Why?
|
Laryngeal Neoplasms | 1 | 2007 | 514 | 0.010 |
Why?
|
Meta-Analysis as Topic | 1 | 2008 | 1376 | 0.010 |
Why?
|
Organ Size | 1 | 2008 | 2254 | 0.010 |
Why?
|
Cerebrospinal Fluid | 1 | 2006 | 544 | 0.010 |
Why?
|
Neoplastic Stem Cells | 1 | 2011 | 1347 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2010 | 1131 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 2379 | 0.010 |
Why?
|
HIV Infections | 1 | 2008 | 17165 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 2010 | 1174 | 0.010 |
Why?
|
Wrist | 1 | 2003 | 219 | 0.010 |
Why?
|
Temporomandibular Joint | 1 | 2003 | 196 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2010 | 4899 | 0.010 |
Why?
|
Treatment Failure | 1 | 2008 | 2648 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2008 | 21025 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2011 | 2640 | 0.010 |
Why?
|
Up-Regulation | 1 | 2009 | 4122 | 0.010 |
Why?
|
Orbit | 1 | 2003 | 446 | 0.010 |
Why?
|
Radiotherapy | 1 | 2007 | 1504 | 0.010 |
Why?
|
Antitubercular Agents | 1 | 2008 | 1373 | 0.010 |
Why?
|
Reference Values | 1 | 2006 | 4925 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2010 | 8552 | 0.010 |
Why?
|
Mycobacterium tuberculosis | 1 | 2008 | 1903 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2009 | 9530 | 0.010 |
Why?
|
Poverty | 1 | 2008 | 2695 | 0.010 |
Why?
|
Artificial Intelligence | 1 | 2011 | 2557 | 0.010 |
Why?
|
United States | 1 | 2024 | 72461 | 0.010 |
Why?
|
Equipment Design | 1 | 2003 | 3520 | 0.010 |
Why?
|
Phantoms, Imaging | 1 | 2003 | 2512 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2008 | 5253 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 2008 | 4491 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2008 | 8056 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2007 | 4024 | 0.010 |
Why?
|
Biopsy | 1 | 2003 | 6771 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2007 | 6465 | 0.010 |
Why?
|
Cerebral Cortex | 1 | 2006 | 5761 | 0.010 |
Why?
|
Electroencephalography | 1 | 2003 | 6189 | 0.000 |
Why?
|
Child | 1 | 2008 | 79806 | 0.000 |
Why?
|
Adolescent | 1 | 2008 | 87810 | 0.000 |
Why?
|